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ABSTRACT
Hepatitis B is one of the most frequent post-transfusion infections. Occult hepatitis B 
infection (OBI) is a form of hepatitis B infection in which, despite the presence of HBV-
DNA in the serum and hepatocytes of the carrier, HBsAg is absent. In addition to the 
risk of transmission through the transfusion of infected blood, reactivation of hepati-
tis B in OBI patients and recipients of their blood can lead to cirrhosis, hepatic cancer, 
and reactivation of viral replication in the carrier. Therefore, effective assays to assess 
and screen for OBI in blood donors are of paramount importance and require urgent 
attention. Recently, several investigations in various regions of Iran have reported OBI 
in blood donors. In response, there has been a drive to apply more specific, sensitive, 
and accurate methods for the detection of HBV, which should become an obligatory 
screening process for all blood transfusion services. In this review, we address the 
progression of occult hepatitis B and the common problems associated with occult 
hepatitis B worldwide. Finally, we reflect on the research and screening that is being 
performed in Iran to deal with this problem.
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  Implication for health policy/practice/research/medical education:
Occult HBV infection (OBI) is a potential risk factor for post transfusion hepatitis B. Based on recent reports, this review aims to pres-
ent the current status of OBI prevalence among worldwide blood donors, common problems associated with OBI as well as useful 
tests for HBV screening.
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1. Background
Hepatitis B Virus (HBV) is one of the most frequent and 
detrimental causes of liver infection in humans (1). The 
most commonly noted symptoms of HBV-related hepa-
titis are jaundice, orangeade skin, and ophthalmia-pro-
tein, which is accompanied by increased bilirubin that 
results from the destruction of the liver cells that would 
normally process these proteins (2). According to the lat-
est reports, more than 2 billion people worldwide have 
serological markers of HBV, and more than 360 million 
of these are suffering from chronic HBV infection (3). To 
decrease the risk of post-transfusion hepatitis (PTH) in 
the  Iranian  blood  transfusion  service  (IBTS),  all  blood 
units  and  blood  components  are  screened  for  HBsAg 
using  ELISA  (4).  Despite  rigorous  screening  across  the Hepat Mon. 2011;11(9):714-718
715 Occult HBV Infection in Blood Donors Kazemi Arababadi M et al.
nation using modern equipment and internationally ac-
cepted screening methods to detect HBV, cases of PTH are 
still reported (5). Hepatitis B infection is categorized into 
5 clinical forms: (1) acute, (2) chronic, (3) fulminate, (4) 
asymptomatic, and (5) occult HBV infection (OBI) (6). OBI 
is a form of long-term HBV infection; however, the clini-
cal symptoms are undefined and differ from those of the 
previous  described  forms  of  HBV  (7).  OBI  differs  from 
asymptomatic HBV infection in that although carriers 
are serologically negative for HBsAg, HBV-DNA is present 
in the serum (8). Due to its particular properties, OBI is 
not detected by the common HBV assays, and it is thus 
capable of creating significant problems for blood trans-
fusion services (9). Therefore, in this review article, we 
consider different aspects of OBI, such as its prevalence 
in Iran and the throughout world, and assess the value of 
some serological diagnostic methods regularly used for 
OBI detection.
2. Clinical Symptoms Associated with OBI
Reactivation or low-level activity of hepatitis B virus in 
patients with OBI has been shown to lead to the develop-
ment of other clinical disorders. Therefore, several re-
search groups have focused on the correlation between 
hepatitis B infection and the onset of related clinical dis-
orders. The clinical symptoms of OBI are mainly catego-
rized into the following groups:
2.1. OBI and Chronic Liver Disease
It is well established that individuals who survive acute 
hepatitis B infection may shift to OBI (10), and despite 
regular examinations and clinical follow up for several 
years thereafter, mild necrotic inflammation can be ob-
served in the liver tissue (10). It could be speculated that, 
although OBI does not exhibit clinically distinct symp-
toms, the low-level viral replication and viral gene ex-
pression can initiate an immune response against hepa-
tocytes, which is sufficient to generate liver necrosis (10). 
Moreover, it has also been suggested that the severity of 
liver injury increases when chronic HCV carriers are co-
infected with trace HBV particles by way of OBI (11-13), and 
that fibrosis and cirrhosis may occur in conjunction with 
OBI (14). In general, it appears that any liver damage in 
the presence of residual HBV or OBI could initiate an im-
mune response that can result in severe liver damage.
2.2. OBI and Hepatocellular Carcinoma
OBI is a possible risk factor for hepatocellular carcino-
ma (HCC) (15, 16). The following 3 situations have been 
well established as important in transducing OBI to in-
duce HCC: 1) Merging of the HBV genome with a patient’s 
chromosome, 2) Long-term inflammatory necrosis dur-
ing OBI, and 3) cirrhosis that subsequently develops into 
OBI (16). The exact steps required for this progression are 
not clear, and additional studies are required to draw a 
definitive conclusion regarding the effect of OBI in in-
ducing HCC.
3. Transmission and Activation of OBI
OBI is considered a high-risk factor for both blood do-
nors (due to the potential risk of hepatitis B reactivation) 
and recipients (due to the risk of infection transmission), 
which is described below.
3.1. Transmission of Infection
All OBI carriers are predisposed to transmitting HBV via 
blood transfusion and organ transplantation, especially 
liver allograft transplantation (17, 18). However, it should 
be  mentioned,  that  as  a  result  of  the  development  of 
screening methods and programs for blood transfusion 
services worldwide, the incidence of PTH has decreased 
significantly.  Despite  these  measures,  some  countries 
are still struggling with HBV transmission through these 
mechanisms (17). For example, in the Asian region, sev-
eral cases of PTH have been reported in India and Taiwan 
(19, 20). OBI transmission via organ transplantation has 
also been reported (18). The risk of HBV transmission via 
OBI  patients  is  enhanced  in  hepatic  allograft  engraft-
ment since hepatocytes are the main source of HBV (21). 
The risk of PTH from OBI patients is lower in heart (22) 
and renal transplantation (23), while bone marrow trans-
plantation carries the lowest risk of PTH (24). Some stud-
ies  have  reported  that  blood  containing  anti-HBc  and 
anti-HBs, does not appear to transmit HBV components, 
even though the viral load ranges between 20 and 500 
IU/mL (25). For example, in a recent look-back study, 49 
blood transfusion recipients were traced to 10 donors 
with OBI. However, the results showed that only 1 recipi-
ent had an HBV strain with 95% sequence homology to 
that of the donor (25), suggesting that the majority of 
transfusion patients that subsequently developed hepa-
titis B did not contract the disease via the OBI donor. Fur-
thermore, they reported that after inoculation of 2 OBI 
donor serum samples into 4 chimeric mice, only 1 mouse 
subsequently had measurable HBV DNA (25). This contro-
versy needs further studies to be resolved.
3.2. OBI Reactivation
The unknown mechanisms that appear to suppress the 
replication and gene expression of HBV, along with the 
inability  of  the  immune  system  to  facilitate  complete 
clearance of HBV are the primary reasons OBI becomes 
established (26). It would appear that under any condi-
tion that leads to immune deficiency, such as AIDS or 
chemotherapy, HBV can be reactivated and commence 
a program of viral replication and gene expression that 
is subsequently followed by an active or fulminant form 
of hepatitis B infection (27, 28). The functional reactiva-
tion of HBV eventually leads to a systematic immune re-
sponse of memory T cells against infected hepatocytes, 
which progresses to liver inflammation and viral hepa-
titis  (28).  In  addition  to  the  abovementioned  diseases 
and treatments that lead to suppression of the immune 
system, some background disorders, including hemato-Hepat Mon. 2011;11(9):714-718
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logical malignancies (29) and allograft transplantations 
of bone marrow and other organs (30, 31), can cause OBI 
reactivation.
4. Prevalence of OBI among National and 
International Blood Donors
Published evidence indicates that OBI is spread widely 
throughout  the  world,  and  patients  co-infected  with 
chronic hepatitis C infection are at increased risk (10, 
32).  Moreover,  investigators  believe  that  several  other 
factors,  in  addition  to  chronic  HCV,  may  also  contrib-
ute  to  the  prevalence  of  OBI,  including  geographical, 
epidemiological, and ethnic factors (33). For instance, we 
have not observed any cases of OBI among HCV-infected 
thalassemia  and  hemodialysis  patients  in  the  Kerman 
province of Iran (33, 34). In addition to HCV-infected pa-
tients, 45% of intravenous narcotic users (35) and 51% of 
patients with hemophilia (36) have been shown to suffer 
from OBI. A wide range of OBI (0–36%) has been reported 
in hemodialysis patients (11, 13, 34). Altogether, these data 
indicate that the prevalence of OBI among blood donors 
varies from country to country in different parts of the 
world. For example, in the European countries of Poland, 
Italy, Spain, and Germany, OBI prevalence rates of 0.006%, 
0.22%, 0.05%, and 0.0006%, respectively, have been report-
OBI Condition, 
No.
Total, 
No.
OBI, 
%
Iran
Tehran (40)
Rafsanjan (43)
Shiraz (39)
Isfahan (43)
Rafsanjan (4)
Zahedan (42)
3
4
16
5
57
3
2,000
270
2,000
545
3,700
110
0.15
1.48
0.8
0.9
1.54
2.72
Poland
Totals from different 
geographical regions (37)
17 250,191 0.006
   Italy
Rome (37)
Turin (37)
Messina (10)
8
18
16
35,016
236,708
98
0.02
0.007
16.3
Spain
Barcelona (37)
Valencia (37)
8
12
15,545
117,829
0.05
0.01
Germany
Frankfort (37) 7 1,348,759 0.0006
Mexican
Mexico city (51)
Oman (52)
17
0
158
200
0.006
0.0
Brazil
Brasilia (53) 5 150 3.3
South Korea
Seoul (41) 7 1,047 0.7
Table 1. Prevalence of OBI in Iran and Several Other Countries. The Table Shows the Occurrence of OBI in Blood Donors in Iranian Compared to that in Blood 
Donors in Other Counties. The Results Were Obtained from Several Research Groups, and the Appropriate References Are Cited.
ed (37) (Table 1). Our previous results in Isfahan showed 
that 9% of HBsAg- blood donors were HBV-DNA+, while 
1.43% of Rafsanjan blood donors were HBsAg-/HBV-DNA+ 
(38). Behbahani et al. and Amini et al. reported that 0.8% 
and 0.15% of HBsAg- blood donors in Shiraz and Tehran, 
respectively, were HBV-DNA+ (39, 40). As described above, 
most  studies  evaluating  OBI  have  been  performed  in 
blood donors, and only a small number of studies have 
evaluated OBI in the general population. For example, 
Song et al. reported that the rate of OBI in the general 
adult population of Korea was 0.7% (41). Raimondo and 
colleagues  researched  OBI  in  individuals  without  he-
patic disease who underwent liver resection or needle 
biopsy during abdominal surgery (10). They showed that 
1/6 of the Italian general population is a carrier of occult 
HBV infection (10). In addition, Sharifi et al. reported that 
3 out of 110 anti-HBc-positive family members of patients 
with acute or chronic HBV infection suffer from OBI (42). 
Although there is minimal data available regarding the 
prevalence of OBI in the general population, based on 
the results of Song et al. (41) and Sharifi et al. (42), it seems 
that the prevalence of OBI in the general population is 
higher than that in blood donors. This may be related 
to the fact that blood donors are screened for HBV infec-
tion; therefore, it is detected as soon as possible and in-
fected individuals are excluded from donation. In addi-Hepat Mon. 2011;11(9):714-718
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tion, it seems that the prevalence of OBI in blood donors 
has a regional variance, not only internationally but also 
nationally. In Iran, the infection rate ranges from 0.8% in 
Shiraz to 2.72% in Zahedan (Table 1). This national variance 
may be related to the fact that the prevalence of HBV in-
fection is highest in Southeastern Iran (41), which has led 
to increased incidence of OBI, or perhaps the blood do-
nors evaluated in our studies were more expansive than 
in other reports (4, 43).
5. Diagnosis of OBI
Obviously, the best method for the diagnosis of OBI is 
the examination of liver cells for the presence of HBV-
DNA (10). However, due to the invasive nature of biopsy 
and the possibility of undesirable injuries to the liver 
during preparation, most current OBI studies are per-
formed on peripheral blood samples (10). A patient who 
is HBsAg-/HBV-DNA+ and entirely free of any clinical symp-
toms of hepatitis and jaundice is considered to have OBI 
(44). Clinical researchers worldwide have paid special at-
tention to the application of hepatitis B core antibodies 
(HBc-Ab; also referred to as anti-HBc) for the rejection of 
at-risk blood units and blood components in blood trans-
fusion services (1). HBc-Ab is well documented as the first 
detectable circulating antibody against HBV, which has 
the highest titer among antibodies (1). Therefore, detec-
tion of this antibody is a useful confirmatory tool that 
can be used in parallel with HBsAg (44). In some coun-
tries,  including  the  USA  and  Japan,  parallel  screening 
for HBsAg and HBc-Ab is performed in all donor samples 
(17, 45); in contrast, in India, HBc-Ab is not in the screen-
ing program for blood transfusions (46). A wide variety 
of studies have examined the detection of this antibody 
among  Iranian  volunteer  blood  donors.  Our  previous 
studies in Esfahan (47) and Rafsanjan blood donors (4, 
43) showed HBc-Ab frequencies of 8% and 5.18%–9.5%, re-
spectively. Other research groups have reported the rates 
of HBc-Ab antibody in different cities of Iran, including 
6.5%, 11.5%, 4.8%, and 4.8% in Shiraz, Tehran, Boroojerd, and 
Khoramabad, respectively (39, 40, 48). The reasons for 
the discrepancies in these results from different teams of 
investigators in various parts of the world (Table 1) could 
likely be categorized as follows:
1. Different sample sizes in the studies
2. The use of different laboratory equipment and mea-
surement kits with different specificities and sensitivi-
ties
3.  Different  racial,  ethnic,  and  genetic  backgrounds, 
which can often affect the humoral immune response 
to HBV, leading to differences in HBc-Ab production (49, 
50)
In  conclusion,  according  to  the  abovementioned  re-
ports, it seems that the directors of Iranian blood trans-
fusion services are in the best position to decide (based 
on scientific and economic criteria) how to implement 
regular  screening  for  HBc-Ab  in  donated  blood  units 
with a view to reduce the risk of post-transfusion and 
post-surgery transmission of HBV.
6. Conclusion
Due to the high prevalence of HBc-Ab and OBI in Ira-
nian blood donors, the authors of this article suggest a 
screening program for HBc-Ab with the use of commer-
cial kits. We also propose the use of PCR-based screening 
programs for diagnosis of OBI in all IBTS.
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